These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19506257)

  • 1. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels.
    Steinberg D; Witztum JL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9546-7. PubMed ID: 19506257
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G; Qian YW; Kowala MC; Konrad RJ
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New weapon in fighting atherosclerosis: effective inhibition of circulating low density lipoprotein cholesterol.
    Ginter E; Simko V
    Bratisl Lek Listy; 2014; 115(12):741-2. PubMed ID: 25520219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 7. [PCSK9 inhibition--A new era in cholesterol treatment].
    Olsson A
    Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 Inhibitors: potential in cardiovascular therapeutics.
    Do RQ; Vogel RA; Schwartz GG
    Curr Cardiol Rep; 2013 Mar; 15(3):345. PubMed ID: 23338726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics. Simple genetics for a complex disease.
    Cohen JC; Hobbs HH
    Science; 2013 May; 340(6133):689-90. PubMed ID: 23661745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 15. New Pharmacological Approaches to Target PCSK9.
    Catapano AL; Pirillo A; Norata GD
    Curr Atheroscler Rep; 2020 Jun; 22(7):24. PubMed ID: 32495301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
    Kirchhofer D; Burdick DJ; Skelton NJ; Zhang Y; Ultsch M
    Biochem Soc Trans; 2020 Aug; 48(4):1323-1336. PubMed ID: 32794575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.